Mark J. Levis

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Catherine C. Smith, Qi Wang, Chen-Shan Chin et al. · Nature · 2012 · 745 citations

Medicine, Genetics, Hematology +13

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl Cramer et al. · Blood · 2009 · 644 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

B. Douglas Smith, Mark J. Levis, Miloslav Beran et al. · Blood · 2004 · 629 citations

Medicine, Oncology, Pharmacology +11

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

Zhihong Zeng, Yue Shi, Ismael Samudio et al. · Blood · 2008 · 512 citations · Full text

Medicine, Oncology, Pharmacology +14